References
- Jassat W, KarimAS Mudara C, Welch R, Ozougwu L, Groome M, Govender N, Von Gottberg A, Wolter N, Blumberg L, Cohen C. Clinical severity of COVID-19 patients admitted to hospitals in Gauteng, South Africa during the omicron-dominant fourth wave. SSRN [Preprint]. 2021. doi:10.2139/ssrn.3996320.
- UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England. 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1045619/Technical-Briefing-31-Dec-2021-Omicron_severity_update.pdf.
- Wilhelm A, Widera M, Grikscheit K, Toptan T, Schenk B, Pallas C, Metzler M, Kohmer N, Hoehl S, Helfritz FA, et al. Reduced neutralization of SARS-CoV-2 omicron variant by vaccine sera and monoclonal antibodies. MedRxiv [Preprint]. 2021. doi:10.1101/2021.12.07.21267432.
- Nemet I, Kliker L, Lustig Y, Zuckerman NS, Erster O, Cohen C, Kreiss Y, Alroy-Preis S, Regev-Yochay G, Mendelson E, et al. Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection. MedRxiv [Preprint]. 2021. doi:10.1101/2021.12.13.21267670.
- Cele S, Jackson L, Khoury DS, Khan K, Moyo-Gwete T, Tegally H, San JE, Cromer D, Scheepers C, Amoako D, et al. SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. MedRxiv [Preprint]. 2021. doi:10.1101/2021.12.08.21267417.
- Hansen CH, Schelde AB, Moustsen-Helm IR, Emborg HD, Krause TG, Mølbak K, Valentiner-Branth P. Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: a Danish cohort study. MedRxiv [Preprint]. 2021. doi:10.1101/2021.12.20.21267966.
- Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, Gower C, Kall M, Groves N, O’Connell AM, et al. Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern. MedRxiv [Preprint]. 2021. doi:10.1101/2021.12.14.21267615.
- Zhang P, Narayanan E, Liu Q, Tsybovsky Y, Boswell K, Ding S, Hu Z, Follmann D, Lin Y, Miao H, et al. A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques. Nat Med. 2021;27(12):2234–2. doi:10.1038/s41591-021-01574-5.